Baidu
map

2018 AAN/AES实践指南:新型抗癫痫药的疗效和耐受性——第一部分:新发癫痫的治疗

2018-06-13 美国神经病学学会 Neurology. 2018 Jun 13.

2018年6月,美国神经病学学会(AAN)联合美国癫痫学会(AES)共同更新发布了新型抗癫痫药的疗效和耐受性指南,该指南是对2004年新发局灶或全身性癫痫的二线和三线抗癫痫治疗指南的更新。新版主要包括两部分内容,分别为新发癫痫的治疗以及难治性癫痫的治疗,此为第一部分。

中文标题:

2018 AAN/AES实践指南:新型抗癫痫药的疗效和耐受性——第一部分:新发癫痫的治疗

英文标题:

Practice guideline update summary: Efficacy andtolerability of the new antiepileptic drugs I:Treatment of new-onset epilepsy

发布机构:

美国神经病学学会

发布日期:

2018-06-13

简要介绍:

2018年6月,美国神经病学学会(AAN)联合美国癫痫学会(AES)共同更新发布了新型抗癫痫药的疗效和耐受性指南,该指南是对2004年新发局灶或全身性癫痫的二线和三线抗癫痫治疗指南的更新。新版主要包括两部分内容,分别为新发癫痫的治疗以及难治性癫痫的治疗,此为第一部分。 

拓展指南:癫痫相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2018 AAN/AES实践指南:新型抗癫痫药的疗效和耐受性——第一部分:新发癫痫的治疗)] GetToolGuiderByIdResponse(projectId=1, id=b0f441c00160e9a7, title=2018 AAN/AES实践指南:新型抗癫痫药的疗效和耐受性——第一部分:新发癫痫的治疗, enTitle=Practice guideline update summary: Efficacy andtolerability of the new antiepileptic drugs I:Treatment of new-onset epilepsy, guiderFrom=Neurology. 2018 Jun 13., authorId=null, author=, summary=2018年6月,美国神经病学学会(AAN)联合美国癫痫学会(AES)共同更新发布了新型抗癫痫药的疗效和耐受性指南,该指南是对2004年新发局灶或全身性癫痫的二线和三线抗癫痫治疗指南的更新。新版主要包括两部分内容,分别为新发癫痫的治疗以及难治性癫痫的治疗,此为第一部分。 , cover=, journalId=null, articlesId=null, associationId=37, associationName=美国神经病学学会, associationIntro=美国神经病学学会成立于1948年,是一个由24,000神经学家和神经科专业人士国际性的专业学会,它致力于推动以病人为中心的,最高质量的神经疾病的治疗。每名神经病学家均是在脑以及神经系统疾病的诊断,治疗和处理方面经过专业培训的医生。其官方期刊是Neurology。学会开发临床实践指南,每个指南具体的临床建议,都是基于严格的和所有可行的科学数据进行的综合评价制定的。, copyright=0, guiderPublishedTime=Wed Jun 13 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>2018年6月,美国神经病学学会(AAN)联合美国癫痫学会(AES)共同更新发布了新型抗癫痫药的疗效和耐受性指南,该指南是对2004年新发局灶或全身性癫痫的二线和三线抗癫痫治疗指南的更新。新版主要包括两部分内容,分别为新发癫痫的治疗以及难治性癫痫的治疗,此为第一部分。 </div> <div><br> </div>拓展指南:<strong>与<font color=red>癫痫</font>相关指南:</strong><br><ul><li><a href="//m.capotfarm.com/guideline/show_article.do?id=ac7831c00160e093" title="2018 ILAE循证建议:成人和儿童癫痫患者的心理治疗" target=_blank>2018 ILAE循证建议:成人和儿童癫痫患者的心理治疗</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=65f241c001602884" title="2018 国际生酮饮食研究组建议:优化接受饮食疗法治疗癫痫的儿童患者的临床管理" target=_blank>2018 国际生酮饮食研究组建议:优化接受饮食疗法治疗癫痫的儿童患者的临床管理</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=d83011c0015ae384" title="中医儿科临床诊疗指南·小儿癫痫( 修订)" target=_blank>中医儿科临床诊疗指南·小儿癫痫( 修订)</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=423261c00150e57d" title="2017 安大略癫痫小组建议:癫痫儿童到成人过渡的护理" target=_blank>2017 安大略癫痫小组建议:癫痫儿童到成人过渡的护理</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=f9e7f1c001a61044" title="如何记录癫痫高频振荡:实践指南 2017" target=_blank>如何记录癫痫高频振荡:实践指南 2017</a></li> 更多信息请点击:<a href="//m.capotfarm.com/guideline/list.do?q=%E7%99%AB%E7%97%AB" target=_blank>有关癫痫更多指南</a></ul>, tagList=[TagDto(tagId=76878, tagName=新型抗癫痫药), TagDto(tagId=584, tagName=癫痫)], categoryList=[CategoryDto(categoryId=17, categoryName=神经科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=1, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8276, appHits=434, showAppHits=0, pcHits=5423, showPcHits=3785, likes=158, shares=34, comments=6, approvalStatus=1, publishedTime=Wed Jun 27 20:57:59 CST 2018, publishedTimeString=2018-06-13, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Wed Jun 27 20:57:59 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 18:55:32 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018 AAN/AES实践指南:新型抗癫痫药的疗效和耐受性——第一部分:新发癫痫的治疗)])
2018 AAN/AES实践指南:新型抗癫痫药的疗效和耐受性——第一部分:新发癫痫的治疗
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=976557, encodeId=46169e655713, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210624/c6a1d318f2354ba989f61b3296c491de/861d56b1ad5348989e5f201d47bcd50b.jpg, createdBy=da095432088, createdName=寇药师, createdTime=Thu Jun 24 16:37:41 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976552, encodeId=e8169e6552b0, content=希望能下载, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210624/c6a1d318f2354ba989f61b3296c491de/861d56b1ad5348989e5f201d47bcd50b.jpg, createdBy=da095432088, createdName=寇药师, createdTime=Thu Jun 24 16:30:45 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915737, encodeId=4cc9915e377c, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>仍需努力, beContent=null, objectType=guider, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201129/3b1d8203775440bab5c196bf59147dde/f97badf4d4b6474fb7c2dcaeeb45a00f.jpg, createdBy=0fc95340195, createdName=崇山峻岭, createdTime=Tue Jan 12 00:21:47 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327536, encodeId=3d4b32e53604, content=不错的文章值得拥有哦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Jun 27 23:16:34 CST 2018, time=2018-06-27, status=1, ipAttribution=)]
    2021-06-24 寇药师

    感谢

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=976557, encodeId=46169e655713, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210624/c6a1d318f2354ba989f61b3296c491de/861d56b1ad5348989e5f201d47bcd50b.jpg, createdBy=da095432088, createdName=寇药师, createdTime=Thu Jun 24 16:37:41 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976552, encodeId=e8169e6552b0, content=希望能下载, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210624/c6a1d318f2354ba989f61b3296c491de/861d56b1ad5348989e5f201d47bcd50b.jpg, createdBy=da095432088, createdName=寇药师, createdTime=Thu Jun 24 16:30:45 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915737, encodeId=4cc9915e377c, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>仍需努力, beContent=null, objectType=guider, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201129/3b1d8203775440bab5c196bf59147dde/f97badf4d4b6474fb7c2dcaeeb45a00f.jpg, createdBy=0fc95340195, createdName=崇山峻岭, createdTime=Tue Jan 12 00:21:47 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327536, encodeId=3d4b32e53604, content=不错的文章值得拥有哦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Jun 27 23:16:34 CST 2018, time=2018-06-27, status=1, ipAttribution=)]
    2021-06-24 寇药师

    希望能下载

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=976557, encodeId=46169e655713, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210624/c6a1d318f2354ba989f61b3296c491de/861d56b1ad5348989e5f201d47bcd50b.jpg, createdBy=da095432088, createdName=寇药师, createdTime=Thu Jun 24 16:37:41 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976552, encodeId=e8169e6552b0, content=希望能下载, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210624/c6a1d318f2354ba989f61b3296c491de/861d56b1ad5348989e5f201d47bcd50b.jpg, createdBy=da095432088, createdName=寇药师, createdTime=Thu Jun 24 16:30:45 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915737, encodeId=4cc9915e377c, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>仍需努力, beContent=null, objectType=guider, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201129/3b1d8203775440bab5c196bf59147dde/f97badf4d4b6474fb7c2dcaeeb45a00f.jpg, createdBy=0fc95340195, createdName=崇山峻岭, createdTime=Tue Jan 12 00:21:47 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327536, encodeId=3d4b32e53604, content=不错的文章值得拥有哦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Jun 27 23:16:34 CST 2018, time=2018-06-27, status=1, ipAttribution=)]
    2021-01-12 崇山峻岭

    #学习#仍需努力

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=976557, encodeId=46169e655713, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210624/c6a1d318f2354ba989f61b3296c491de/861d56b1ad5348989e5f201d47bcd50b.jpg, createdBy=da095432088, createdName=寇药师, createdTime=Thu Jun 24 16:37:41 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976552, encodeId=e8169e6552b0, content=希望能下载, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210624/c6a1d318f2354ba989f61b3296c491de/861d56b1ad5348989e5f201d47bcd50b.jpg, createdBy=da095432088, createdName=寇药师, createdTime=Thu Jun 24 16:30:45 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915737, encodeId=4cc9915e377c, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>仍需努力, beContent=null, objectType=guider, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201129/3b1d8203775440bab5c196bf59147dde/f97badf4d4b6474fb7c2dcaeeb45a00f.jpg, createdBy=0fc95340195, createdName=崇山峻岭, createdTime=Tue Jan 12 00:21:47 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327536, encodeId=3d4b32e53604, content=不错的文章值得拥有哦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Jun 27 23:16:34 CST 2018, time=2018-06-27, status=1, ipAttribution=)]
    2018-06-27 1e1b8538m79(暂无匿称)

    不错的文章值得拥有哦

    0

Baidu
map
Baidu
map
Baidu
map